{"id":105191,"date":"2021-02-19T03:00:00","date_gmt":"2021-02-19T03:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2832394"},"modified":"2021-02-19T03:00:00","modified_gmt":"2021-02-19T03:00:00","slug":"covid-19-impact-on-global-prostate-cancer-diagnostics-market-recovery-analysisrevenuesupply-demandinvestment-and-forecast-2027","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2021\/02\/19\/covid-19-impact-on-global-prostate-cancer-diagnostics-market-recovery-analysisrevenuesupply-demandinvestment-and-forecast-2027\/","title":{"rendered":"COVID-19 Impact On Global Prostate Cancer Diagnostics Market Recovery Analysis,Revenue,Supply Demand,Investment And Forecast 2027"},"content":{"rendered":"

\"COVID-19 <\/a> <\/p>\n

iCrowdNewswire <\/strong>  Feb 18, 2021  10:00 PM ET<\/span><\/p>\n

Prostate gland is situated in the pelvis below the bladder. Prostate cancer is the medical condition which is an unbounded and unusual growth of cells in the prostate glands of the male. Growth of healthcare expenditure and innovation of new technologies in minimally invasive surgeries to patients due to early post-operative recovery are also likely to driven the global prostate cancer diagnostics market growth.<\/p>\n

Rise in prevalence of prostate cancer is key driving factor which is expected boost the global prostate cancer diagnostics market growth. For instant, as per the National Cancer Institute in United State around 174,650 new cases were diagnosed in year 2019. Furthermore, growing technological advancements in diagnostic tests are expected to further propel the global prostate cancer diagnostics market growth over the forecast period. Also, increase in government support and initiatives to develop new technologies to enhance diagnosis will positively influence the market growth. The increase in number of number of new market entrants is another driving factor anticipated to drive the market growth in near future. In addition to that, increase in product approvals by USFDA is projected to support the global prostate cancer diagnostics market growth.<\/p>\n

Get Sample Copy of this Report @ <\/strong>https:\/\/qualiketresearch.com\/request-sample\/Prostate-Cancer-Diagnostics-Market\/request-sample<\/strong><\/a><\/p>\n

The high cost of prostate cancer drugs is the major restrain which is expected to hinder the global prostate cancer diagnostics market growth. Also, low success rate of clinical trials will affect the global prostate cancer diagnostics market growth over the forecast period.<\/p>\n

Market Segmentation<\/strong><\/p>\n

Global Prostate Cancer Diagnostics Market is segmented into type such as Benign Prostatic Hyperplasia, Prostatic Adenocarcinoma, Small Cell Carcinoma, and Others, by diagnosis, such as Tissue Biopsy, Transrectal Ultrasound, Clinical Laboratory Examination, Urine Testing, and Prostate Specific Antigen Testing. Further, market is segmented into treatment such as Surgery, Radiation Therapy, and Therapeutics (Hormone Therapy, Chemotherapy, and Others).<\/p>\n

Also, Global Prostate Cancer Diagnostics Market is segmented five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.<\/p>\n

Market Key Players<\/strong><\/p>\n

Various key players are discussed in this report including Abbott, MDxHealth, Genomic Health, 3D Signatures, OPKO Health, INC., Siemens Healthcare GmbH, DiaSorin S.p.A, F. Hoffman La Roche Ltd., BioMerieux SA, Beckman Coulter, INC., and Myriad Genetic Inc.<\/p>\n

Market Taxonomy<\/strong><\/p>\n

By Type<\/strong><\/p>\n